2-Decene, 2,6-dimethyl-9-nitro- | 834898-00-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-Decene, 2,6-dimethyl-9-nitro-
• 英文别名: 2,6-dimethyl-9-nitrodec-2-ene
• CAS: 834898-00-9
• 化学式: C12H23NO2
• 分子量: 213.32
• InChiKey: PGVHPYNHAPMHHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
  申请人：Rose D. Seth

  公开号：US20050026812A1

  公开（公告）日：2005-02-03

  Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).

  共轭硝基烯烃化合物可以阻碍或预防癌细胞在细胞培养和癌症患者中的增殖，这可能导致肿瘤大小的减小和/或癌症的消失。这些化合物可能通过干扰癌细胞的生物化学作用来发挥作用，其中类似于法尼醇和戊二烯基的异戊二烯基基团与各种致癌蛋白质如Ras、RhoA、RhoB或其他与生长相关的细胞蛋白质结合。
• Conjugated Nitro Alkene Anticancer Agents Based on Isoprenoid Metabolism
  申请人：ROSE Seth D.

  公开号：US20080113919A1

  公开（公告）日：2008-05-15

  Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).

  硝基烯烃化合物在细胞培养和癌症患者中阻碍或预防癌细胞增殖，这可能导致肿瘤大小的减小和/或癌症的消失。这些化合物可能通过干扰癌细胞的生物化学作用来发挥作用，其中异戊二烯基和戊二烯基等异戊二烯基类似物与各种致癌蛋白质（如Ras、RhoA、RhoB或其他与生长相关的细胞蛋白质）结合。
• US7312191B2
  申请人：——

  公开号：US7312191B2

  公开（公告）日：2007-12-25
• US7977315B2
  申请人：——

  公开号：US7977315B2

  公开（公告）日：2011-07-12
• [EN] CONJUGATED NITRO ALKENE ANTICANCER AGENTS BASED ON ISOPRENOID METABOLISM<br/>[FR] AGENTS ANTICANCEREUX A BASE DE NITRO-ALCENE CONJUGUE UTILISANT LE METABOLISME DES ISOPRENOIDES
  申请人：ARIZONA DISEASE CONTROL RES CO

  公开号：WO2005016864A1

  公开（公告）日：2005-02-24

  Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).